Cargando…
The emerging role of cancer nanotechnology in the panorama of sarcoma
In the field of nanomedicine a multitude of nanovectors have been developed for cancer application. In this regard, a less exploited target is represented by connective tissue. Sarcoma lesions encompass a wide range of rare entities of mesenchymal origin affecting connective tissues. The extraordina...
Autores principales: | Mercatali, Laura, Vanni, Silvia, Miserocchi, Giacomo, Liverani, Chiara, Spadazzi, Chiara, Cocchi, Claudia, Calabrese, Chiara, Gurrieri, Lorena, Fausti, Valentina, Riva, Nada, Genovese, Damiano, Lucarelli, Enrico, Focarete, Maria Letizia, Ibrahim, Toni, Calabrò, Luana, De Vita, Alessandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618700/ https://www.ncbi.nlm.nih.gov/pubmed/36324885 http://dx.doi.org/10.3389/fbioe.2022.953555 |
Ejemplares similares
-
Myxofibrosarcoma landscape: diagnostic pitfalls, clinical management and future perspectives
por: Vanni, Silvia, et al.
Publicado: (2022) -
A Rationale for the Activity of Bone Target Therapy and Tyrosine Kinase Inhibitor Combination in Giant Cell Tumor of Bone and Desmoplastic Fibroma: Translational Evidences
por: De Vita, Alessandro, et al.
Publicado: (2022) -
Unveiling the Genomic Basis of Chemosensitivity in Sarcomas of the Extremities: An Integrated Approach for an Unmet Clinical Need
por: Vanni, Silvia, et al.
Publicado: (2023) -
Characterization and Drug Sensitivity of a New High-Grade Myxofibrosarcoma Cell Line
por: Miserocchi, Giacomo, et al.
Publicado: (2018) -
mTOR inhibitor and bone-targeted drugs break the vicious cycle between clear-cell renal carcinoma and osteoclasts in an in vitro co-culture model
por: Spadazzi, Chiara, et al.
Publicado: (2019)